Ab interno trabeculotomy was performed using the recently developed XeCl excimer laser in 21 eyes of 21 patients with primary open-angle glaucoma refractory to medical therapy. The patients were followed at the Eye Department of S. Antonio Hospital in Padova, for an average of 25.3 ± 1.3 months. Intraocular pressure (IOP), visual acuity and ocular complications were evaluated. The laser procedure was quick and relatively easy, with minimal manipulation of tissues; complications were clinically insignificant. At the last follow-up, a marked IOP-lowering effect compared to baseline was observed (from 24.8 ± 2.0 to 16.9 ± 2.1 mm Hg; –31.8%, p < 0.0001). Nineteen patients (90.5%) had an IOP lowering of 20% or more; however, 8 of these eyes (38.1%) required additional IOP-lowering medical therapy. The procedure failed in 2 cases (9.5%) despite additional therapy. In conclusion ab interno excimer laser trabeculotomy seems effective to decrease IOP, serves to reduce the number of antiglaucoma medications and is relatively safe, proving to be a promising therapeutic option in glaucoma surgery.

Wilensky JT: The role of medical therapy in the rank order of glaucoma treatment. Curr Opin Ophthalmol 1999;10:109–111.
Feiner L, Piltz-Seymour JR: Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 2003;14:106–111.
Wise B Jr, Witter SL: Argon laser therapy for open angle glaucoma: a pilot study. Arch Ophthalmol 1979;97:319.
Latina MA, Tumbocon JA: Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol 2002;13:94–96.
Juzych MS, Chopra V, Banitt MR, Hughes BA, Kim C, Goulas MT, Shin DH: Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma. Ophthalmology 2004;10:1853–1859.
Dietlein TS, Jacobi PS, Krieglstein GK: Erbium:YAG laser ablation on human trabecular meshwork by contact delivery endoprobes. Ophthalmic Surg Lasers1996;27:939–945.
Vivar A, Lowery J, Rostrepo CL, et al: A one-year follow-up clinical results following gonioscopic laser trabecular ablation (GLTA) with a Ti-sapphire laser for the treatment of glaucoma. Invest Ophthalmol Vis Sci 1996;37:1218.
Myers JS, Katz IJ, Schwartz LW, et al: Gonioscopic ab interno Nd:YLF laser trabeculotomy in human cadaverous eyes. Invest Ophthalmol Vis Sci 1996;37:1206.
Grant WM: Clinical measurements of aqueous outflow. Arch Ophthalmol 1951;46:113–131.
Bill A, Svedbergh B: Scanning electron microscopy studies of the trabecular meshwork and the canal of Schlemm in an attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol 1972;50:295–318.
Rosenquist R, Epstein D, Melamed S, Johnson M, Grant WM: Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomy. Curr Eye Res 1989;8:1233–1240.
Schumann JS, Chang W, Wang N, de Kater AW, Allingham RR: Excimer laser effect on outflow facility and outflow pathway morphology. Invest Ophthalmol Vis Sci 1999;10:1676–1680.
Walker R, Specht H: Theoretical and physical aspects of excimer laser trabeculotomy (ELT) ab interno with the AIDA laser with a wave length of 308 nm. Biomed Tech 2002;47:106–110.
Huang S, Yu M, Feng G, Zhang P, Qiu C: Histopathological study of trabeculum after excimer laser trabeculectomy ab interno. Yan Ke Xue Bao 2001;17:11–15.
Vogel M, Lauritzen K, Quentin CD: Targetted ablation of the trabecular meshwork with excimer laser in primary open-angle glaucoma. Ophthalmologe 1996;94:565–568.
Vogel M, Lauritzen K: Selective excimer laser ablation of the trabecular meshwork: clinical results. Ophthalmologe 1997;94:665–667.
Neuhann T, Scharrer A, Haefliger E: Excimer laser trabecular ablation ab interno (ELT) in the treatment of chronic open-angle glaucoma: a pilot study. Ophthalmochirurgie 2001;13:3–7.
Sourdille P: Study shows ab interno excimer trabeculotomy lowers, controls IOP. Ocul Surg News Europe/Asia-Pacific Ed 2001;12:28.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.